Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRE | P78334 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748 | 0.89 | — | — | |
| SCHEMBL16005555 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL1728563 | 0.87 | — | — | |
| SCHEMBL7783653 | 0.69 | — | — | |
| SCHEMBL161143 | 0.69 | — | — | |
| SCHEMBL9803026 | 0.68 | SLC7A5 (0.46) | LMNAALDH1A1MAPTPTGS2TDP1 | |
| SCHEMBL1251618 | 0.68 | ALDH1A1 (0.38) | LMNAALDH1A1MAPTPTGS2TDP1 | |
| SCHEMBL28424072 | 0.68 | GRIK1 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Alanine SCHEMBL27729429 | 0.68 | ALDH1A1 (0.38) | LMNAALDH1A1MAPTPTGS2TDP1 | |
| SCHEMBL31668204 | 0.68 | CTH (0.35) | LMNAALDH1A1MAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180362583-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | H LEE MOFFITT CANCER CT & RES (US) | 2018-12-20 | — | — | US | disclosed |
| US-10059740-B2 | Integrin interaction inhibitors for the treatment of cancer | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20160257712-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | H LEE MOFFITT CANCER CT & RES (US) | 2016-09-08 | — | — | US | disclosed |
| US-20150071918-A1 | PEPTIDES FOR THE TREATMENT OF CANCER | UNIVERSITY OF SOUTH FLORIDA | 2015-03-12 | — | — | US | disclosed |
| EP-2547693-B1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | H LEE MOFFITT CANCER CT & RES (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8853149-B2 | Integrin interaction inhibitors for the treatment of cancer | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2013170066-A1 | PEPTIDES FOR THE TREATMENT OF CANCER | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130065837-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-03-14 | — | — | US | disclosed |
| EP-2547693-A2 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | H. Lee Moffitt Cancer Center & Research Institute (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011115688-A2 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362583-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | ITGB1, ITGB7, ITGA2B | LMNA 1858/4885ALDH1A1 3715/4885MAPT 3788/4885 |
| US-20130065837-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | ITGB1, ITGB7, ITGA2B | LMNA 1858/4885ALDH1A1 3715/4885MAPT 3788/4885 |
| US-10059740-B2 | Integrin interaction inhibitors for the treatment of cancer | ITGB1, ITGB7, ITGA2B | LMNA 1858/4885ALDH1A1 3715/4885MAPT 3788/4885 |
| US-20160257712-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | ITGB1, ITGB7, ITGA2B | LMNA 1858/4885ALDH1A1 3715/4885MAPT 3788/4885 |
| US-20150071918-A1 | PEPTIDES FOR THE TREATMENT OF CANCER | CD44, PTK2, SDC1 | LMNA 2581/4885ALDH1A1 4215/4885MAPT 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.